- Poster presentation
- Open Access
NGS technology applied to melanoma cell lines
© De Giorgi et al; licensee BioMed Central Ltd. 2013
- Published: 7 November 2013
- Sequencing Technology
- Melanoma Cell Line
- Clinical Trial Design
- Generation Sequencing Technology
- Histopathological Classification
High-throughput sequencing technology challenges the traditional histopathological classification of cancer, and proposes new taxonomies derived from global transcriptional patterns. They provided in-depth of new information that can reframe our understanding of human cancer biology. The novel observations that cancer phenotype characterized by immune effectors mechanisms are commonly observed during acute inflammation reaction. Several studies revealed associations between inflammatory status and a favorable natural history of the disease or a better responsiveness to cancer immune therapy. In the present study we applied RNA-seq analysis of 15 melanoma cells line, extensively classified (genetically, functionally and clinically) to explore the association between their constitutive pSTAT1 activation and the constitutive expression of genes associated with the regulation of the JAK/STAT pathway. With high resolution of sequencing information, we also attempt to identify the genetic determinants responsible for the phenotype (IRF-1, STAT1, Th1) associated with good prognosis and responsiveness to immunotherapy.
Rna-seq was performed using Solexa (Illumina GAII technology). CLC-bio workbench and deFuse algorithm were used for the alignment and for gene fusion analysis respectively.
Information about gene expression levels, splicing variants and fused gene were obtained. Novel fusion genes and mutations which could not be identified by conventional expression analysis were identified. Consistent tumor heterogeneity was observed across all 15 samples.
Next generation sequencing technologies provides a more comprehensive view of cancer mutational landscapes and hereby a better understanding of their pathogenesis. This could be an open interesting perspective for new treatment approaches and clinical trial designs.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.